Core E:Biomarkers Core

项目摘要/摘要 BiomMarkers核心的目的是提供一个组织模式，以加速开发和 批准在孢子项目内和其他项目中将生物学与临床结果联系起来的生物标记测试 核心。这一核心专注于对基于成像和液体的非侵入性分析进行认证，以评估和 通过表征癌症的分子和细胞特征来监测疾病状态 时间到了。通过Biomarkers Core，计划、收集和跟踪人类生物样本的收集 根据IRB批准的临床方案。同意、病人登记和标本采集的过程 在Biomarkers Core的领导下，在临床上进行。Biomarkers Core在临床上的应用 努力覆盖整个前列腺癌疾病连续体的患者。Biomarkers Core还将进行 在它的领导下，FDHT、PSMA和DLL3PET的三种成像协议。这一核心是对 其他孢子核心和MSK资源，包括斯隆分子肿瘤学中心(CMO) 凯特琳研究所(SKI)，人类肿瘤学和病理学计划(HOPP)，临床实验室， 早期药物开发(EDD)服务和其他临床服务。核心的优先级由以下因素决定 基础研究、药物开发和临床实践方面未得到满足的需求，目标是使更多 知情的诊断和治疗决策，从而改善患者的预后。

Project Summary/Abstract The purpose of the Biomarkers Core is to provide an organizational model to accelerate the development and approval of biomarker tests that link biology to clinical outcomes within SPORE projects and across other Cores. This Core is focused on credentialing both imaging-based and liquid non-invasive assays to assess and monitor disease status by characterizing the molecular and cellular features of a cancer as it changes over time. Through the Biomarkers Core, the collection of human biospecimens is scheduled, collected, and tracked under an IRB-approved clinical protocol. The process of consent, patient registration, and specimen collection is undertaken in clinic, under the leadership of the Biomarkers Core. Applied to the clinic, the Biomarkers Core efforts cover patients across the prostate cancer disease continuum. The Biomarkers Core will also conduct under its leadership the three imaging protocols, for FDHT, PSMA, and DLL3 PET. This core complements the other SPORE cores and MSK resources that include the Center for Molecular Oncology (CMO), Sloan Kettering Institute (SKI), the Human Oncology and Pathogenesis Program (HOPP), Clinical Laboratories, the Early Drug Development (EDD) Service, and other clinical services. Priorities for the Core are determined by unmet needs in basic research, drug development, and clinical practice, with the objective of enabling more informed diagnostic and therapeutic decisions so that patient outcomes are improved.